BPC-157 (Body Protection Compound)

Mechanism: Gastric pentadecapeptide that heals the gut lining, upregulates the body's antioxidant system, and promotes systemic tissue repair. Works through nitric oxide pathways and growth factor modulation. Described as capable of "turning off inflammation at a genetic level" in clinical settings. Promotes context-dependent angiogenesis — stimulates vessel growth in damaged tissue while suppressing pathological vessels (e.g. cirrhotic liver). Animal model data shows it inhibited melanoma cell growth and blocked VEGF tumor-signaling, addressing cancer concerns raised about its pro-angiogenic properties. A single injection in a spinal cord injury model produced functional improvements lasting up to 360 days, with the healing cascade persisting long after the peptide cleared the system.

Dosing Protocol:

• Standard dose: 250–500 mcg/day via subcutaneous injection
• Oral BPC-157: Preferred specifically for gut healing — delivers peptide directly to the gut lining
• Cycle: 4–6 weeks on, 2 weeks off; animal data shows no accumulation or tolerance after 7 days daily dosing
• Timeline: Most users report significant improvements within 4–8 weeks
• Injection site: Systemic biodistribution confirmed — injection site does not need to be at the injury; local injection may enhance localized effects

Evidence Quality: Expert opinion (multiple functional medicine practitioners), supported by robust animal studies including spinal cord, liver, and oncology models.

Stacking Guidance:

• BPC-157 + TB-500 ("The Wolverine Stack"): Standard protocol — 500 mcg each daily. BPC-157 handles tissue repair; TB-500 promotes angiogenesis and cellular migration. Clinically used for nagging injuries, slow recovery, and musculoskeletal repair. Case reports include full recovery from rotator cuff tears and claimed superiority over surgical outcomes in some cases.
• BPC-157 + KPV (oral): One of the most effective inflammation reduction protocols per multiple practitioners. Improves gut barrier while generating downstream anti-inflammatory effects throughout the body. Recommended alongside GLP-1 medications for patients with persistent gut issues. Reduces bloating, improves digestion and nutrient absorption.
• BPC-157 + KPV + Larazotide: Three-peptide clinical stack — BPC-157 heals gut lining, KPV blocks NF-kB gene activation, Larazotide repairs tight junctions via the zonulin pathway.

Safety Notes:

• Generally well-tolerated; no documented fatal overdose. Practitioners note endogenous-origin safety profile.
• Ineffective in isolation without addressing underlying inflammation, poor diet, and suboptimal training
• Potential theoretical interaction with blood thinners (limited data)
• Source from 503A compounding pharmacy; research-grade peptides are not equivalent to pharmaceutical-grade
• Critical: Do not combine in a single vial with GHK-Cu — copper ion destroys other peptides in blended vials

Sources: DrJonesDC YouTube (multiple findings), Jay Campbell YouTube, Dr. Purita clinical reports, r/Peptides, PubMed animal studies

---

TB-500 (Thymosin Beta-4)

Mechanism: Promotes new blood vessel growth (angiogenesis) via VEGF upregulation and integrin alpha-V beta-3 receptor expression. Mobilizes bone marrow-derived progenitor cells to damaged tissue. Inhibits TGF-beta/SMAD3 pathway, reducing fibroblast activation by 60% — effectively deprogramming already-activated scar-tissue-producing cells. Shifts immune response from destructive to reparative inflammation by downregulating TNF-alpha and IL-6 while upregulating anti-inflammatory mediators. Evidence base extends significantly beyond musculoskeletal repair into cardiac and renal disease reversal.

Dosing Protocol:

• Standard dose: 500 mcg/day subcutaneous injection
• High-dose (serious injuries): Up to 2,000 mcg/day — clinically used for significant musculoskeletal injuries
• Cycle: 4–6 weeks standard; escalate dose in first 1–2 weeks for acute injuries, then return to maintenance
• Administration: Systemic — injection site independence confirmed; subcutaneous in abdomen or near injury site
• Half-life note: ~5-day half-life — do not pre-mix with BPC-157 (incompatible half-lives; draw separately every time)

Evidence Quality: Multiple peer-reviewed animal studies (cardiac, renal, musculoskeletal 2002–2016); clinical case report of full cardiac/renal disease reversal over 12–24 months.

Key Animal Study Data:

• Reversed myocardial fibrosis 6 weeks post-MI — reduced collagen content, improved ejection fraction (Smart, 2015, Cardiovascular Research)
• Reduced ventricular arrhythmias 67% post-infarction via fibrosis reduction (Worth, 2016, Basic Research in Cardiology)
• Reduced proteinuria 40%, improved renal microvascular perfusion (Badel, 2012)
• Reduced albuminuria 56%, glomerular sclerosis 48% in diabetic nephropathy (Sosne, 2014, American Journal of Pathology)
• Reduced fibroblast activation marker (alpha-SMA) 60% via TGF-beta/SMAD3 inhibition (Sosne, 2013, PLOS ONE)

Stacking Guidance:

• BPC-157 + TB-500 (Wolverine Stack): 500 mcg each daily — complementary mechanisms (tissue repair + vascularization)
• KPV + TB-500 (cardiovascular stack): KPV addresses root-cause systemic inflammation and endothelial function; TB-500 addresses downstream cardiac and structural tissue damage. Described as a comprehensive two-pronged cardiovascular solution.
• Escalated injury protocol: Increase TB-500 to 2,000 mcg while keeping BPC-157 at 500 mcg for the first 1–2 weeks

Safety Notes:

• Well-tolerated at standard doses; high-dose protocols should be clinician-monitored
• Source from 503A compounding pharmacy only
• Do not pre-mix with BPC-157 or GHK-Cu in a single vial

Sources: Jay Campbell YouTube, Dr. Bachmeyer clinical practice, PubMed cardiac/renal animal study series (2002–2016), r/Peptides community

---

GHK-Cu (Copper Peptide)

Mechanism: Tripeptide with copper binding that signals the body to produce collagen rather than directly supplying it — a key mechanistic distinction. Promotes wound healing, collagen synthesis, and extracellular matrix remodeling. Acts as a signaling molecule recruiting repair processes. Demonstrates anti-inflammatory and antioxidant properties and modulates genes involved in inflammation reduction. Specifically highlighted by Dr. Purita as having anti-cancer properties — notably, GHK-Cu is considered safe for cancer patients while BPC-157 and TB-500 are not recommended in that context. Surface changes (skin appearance) expected at 6–12 weeks; structural collagen changes require 3–6 months.

Dosing Protocol:

• Injectable (SubQ): 2–4 mg/day for systemic effects — standard clinical dosing
• Topical: 2% concentration cream/serum for localized skin and wound healing
• Cycle: Injectable 4–6 week cycles; topical can continue through off-cycles
• Co-supplementation: Stack with 30g type II collagen daily + 1,000 mg vitamin C — GHK-Cu signals collagen production; raw materials must be available for the signal to be effective
• Topical layering: Combine systemic injection with topical copper peptide serums + hyaluronic acid and retinoids for dual-route delivery ("hitting the target from both sides")

Evidence Quality: Expert opinion (Dr. Purita, Jay Campbell, functional medicine practitioners); wound healing animal and human observational data; PubMed collagen synthesis studies.

Stacking Guidance:

• BPC-157 + TB-500 + GHK-Cu ("Triple Stack" / "Glow Stack"): Standard protocol at Dr. Purita's stem cell clinic — "works exceptionally well." Each peptide covers a distinct recovery pathway: tissue repair, vascularization, and ECM remodeling/collagen synthesis
• Post-surgical recovery: Specifically recommended for skin removal and post-operative wound healing
• Post-stem cell protocol: Used as part of post-stem cell injection recovery alongside shockwave and red light therapy

Safety Notes:

• Topical application very well-tolerated
• Injectable: pharmaceutical-grade only; source from 503A compounding pharmacy
• Copper accumulation is theoretical at standard doses; worth monitoring in extended use
• Critical — vial compatibility: Do not combine GHK-Cu with any other peptides in a single vial. Copper ion "demolishes" other peptides. Draw GHK-Cu exclusively into its own syringe.
• UV damage counteracts GHK-Cu collagen rebuilding — daily sunscreen is non-negotiable when using for skin/collagen outcomes

Sources: Jay Campbell podcast, Dr. Purita (stem cell and regenerative medicine), DrJonesDC YouTube, PubMed wound healing studies, r/Peptides

---

KPV (Lys-Pro-Val) — v2 Addition

Mechanism: C-terminal tripeptide fragment of alpha-MSH (alpha-melanocyte stimulating hormone). Activates melanocortin receptors (MC1R and related) on immune cells, producing a cascading anti-inflammatory effect that works at the genetic level — enters the cell nucleus and blocks NF-kB, the master inflammatory switch controlling inflammatory gene expression. This shifts macrophages from M1 (pro-inflammatory, MMP-producing) to M2 (anti-inflammatory, tissue-repairing) phenotype via GPCR signaling. Increases T-regulatory cell proliferation and IL-10 production. Works directly on intestinal tight junctions to repair gut barrier integrity — a mechanism GLP-1 medications cannot replicate. Addresses Dr. Bachmeyer's "three biological failures" model: systemic inflammation (MC1R activation), insulin resistance (TNF-alpha reduction, HOMA-IR -35%), and mitochondrial dysfunction (improved glucose uptake).

Described as "immune restoration, not immunosuppression" — it repairs the immune system's natural braking mechanisms (T-regulatory cells) rather than suppressing immune activation like NSAIDs or corticosteroids.

Dosing Protocol:

• Standard anti-inflammatory dose: 300–400 mcg/day subcutaneous injection (HSV protocol data; patient achieved zero outbreaks in 90 days after 8 years of monthly outbreaks)
• Active immune challenge dose: 400 mcg twice daily (800 mcg total) — used in EBV/viral protocols with active cytokine-driven inflammation
• Conservative daily maintenance: ~750 mcg/day (practitioner consensus for general anti-inflammatory use)
• Oral route: Used specifically for gut inflammation — oral KPV + oral BPC-157 is the preferred clinical approach for gut barrier repair
• Cycle: Evidence suggests benefits persist 6 months after discontinuation (cardiovascular cohort data). Cycling not strictly required but recommended for extended protocols.

Evidence Quality: Multiple peer-reviewed studies (cardiovascular outcomes 2014–2019); expert opinion (Dr. Bachmeyer, DrJonesDC); case reports including Hashimoto's-driven inflammation resolution and HSV outbreak elimination. Strongest clinical evidence base of the four peptides in the recovery stack for systemic inflammatory outcomes.

Key Clinical Study Data:

• In 156 established cardiovascular disease patients over 12 weeks: CRP -52%, TNF-alpha -41%, IL-6 -38%, IL-1beta -33%, endothelial vasodilation +28%, coronary artery calcification -11% (CAC typically increases yearly — this is a reversal), 35% reduction in major adverse cardiovascular events at 12-month follow-up. Benefits persisted 6 months after discontinuation (Katana, 2019, Atherosclerosis).
• ICAM-1 -47%, VCAM-1 -52% — transforms arterial walls from "sticky and inflamed" to functional (Katana, 2014, Atherosclerosis)
• Macrophage phenotype shift stops MMP production, stabilizes arterial plaque, prevents fibrous cap thinning and rupture (Katana, 2014, Current Medicinal Chemistry)
• Cardiovascular inflammation patient cohort: KPV reduced TNF-alpha 41%, IL-6 38%, IL-1beta 33% via MC1R activation (Getting, 2016, Inflammation Research)

Stacking Guidance:

• BPC-157 + KPV (oral) — gut repair: Clinically described as one of the most effective inflammation reduction protocols available. KPV acts on tight junctions; BPC-157 heals the lining. Patients report reduced bloating, better digestion, improved nutrient absorption within weeks.
• BPC-157 + KPV + Larazotide — full gut triad: Adds zonulin/tight junction pathway repair. Used in autoimmune protocols, fatty liver disease, and GLP-1 adjunct therapy.
• KPV + TB-500 — cardiovascular stack: Root-cause (KPV targets inflammation and endothelial function) + structural repair (TB-500 addresses fibrosis, scarring, vascular remodeling). Comprehensive two-pronged solution.
• Full Recovery Stack v2: BPC-157 + TB-500 + GHK-Cu + KPV — adds systemic immune regulation and gut-axis repair to the established Wolverine/Triple Stack framework. KPV fills the immune modulation gap that the original three-peptide stack does not address.
• Autoimmune layer: In complex protocols, KPV is layered with BPC-157, Larazotide, Thymosin Alpha-1, LDN, and micro-dosed GLP-1 agents for multi-system anti-inflammatory coverage.

Safety Notes:

• Derived from alpha-MSH, which the body naturally produces — considered inherently safer than synthetic pharmaceuticals per practitioner claims
• Immune restoration rather than suppression — does not blunt immune activation like steroids or NSAIDs
• Not contraindicated in cancer patients (unlike BPC-157 and TB-500 which are flagged for caution in oncology contexts)
• Source from 503A compounding pharmacy

Sources: Dr. Bachmeyer YouTube (cardiovascular series), DrJonesDC YouTube (gut/autoimmune protocols), peer-reviewed studies (Katana 2014/2019, Getting 2016), clinical case reports

---

Recovery Stack v2 — Recommended Protocol Summary

Updated for a 40–55 year-old active individual focused on training recovery, gut health, and systemic inflammation control:

Peptide	Dose	Route	Frequency	Duration
BPC-157	500 mcg	SubQ (abdomen) or Oral (gut focus)	Daily	4–6 weeks
TB-500	500 mcg (up to 2,000 mcg acute)	SubQ (abdomen)	Daily	4–6 weeks
GHK-Cu	2–4 mg injectable or 2% topical	SubQ or topical	Daily	4–6 weeks injectable; ongoing topical
KPV	300–750 mcg	SubQ or Oral (gut focus)	Daily	4–6 weeks; benefits may persist 6 months post-cycle

Cycling: Run the full stack for 4–6 weeks, take 2 weeks off, repeat as needed. GHK-Cu topical and oral KPV/BPC-157 can continue through off-cycles for gut maintenance.

Acute Injury Escalation: Increase TB-500 to 1,000–2,000 mcg/day for the first 1–2 weeks, then return to 500 mcg maintenance dose.

Gut-Focus Protocol Variant: Switch BPC-157 and KPV to oral route. Add Larazotide for full tight-junction repair coverage.

Vial compatibility reminder: Never combine BPC-157, TB-500, or GHK-Cu in a single vial. Draw each separately. GHK-Cu copper ion destroys other peptides. BPC-157 (~1-day half-life) and TB-500 (~5-day half-life) are incompatible for pre-mixing.

Sourcing: All peptides must be obtained from a 503A compounding pharmacy. Research-grade peptides are not suitable for human use.

---

Mechanism Coverage Summary

Recovery Pathway	Primary Peptide	Supporting Peptide
Tissue repair & gut healing	BPC-157	KPV (gut tight junctions)
Angiogenesis & vascularization	TB-500	BPC-157 (injury-context dependent)
Collagen synthesis & ECM remodeling	GHK-Cu	BPC-157 (wound healing)
Systemic inflammation resolution (NF-kB / MC1R)	KPV	TB-500 (cytokine modulation)
Anti-fibrotic / scar prevention	TB-500	BPC-157 (angiogenesis context-switching)
Immune regulation (T-reg / macrophage phenotype)	KPV	TB-500 (M1 to M2 shift)
Progenitor cell mobilization	TB-500	—

v2 update: Added KPV to the Recovery Stack, covering systemic immune modulation and gut-axis repair mechanisms not addressed by BPC-157 + TB-500 + GHK-Cu alone. Full re-synthesis with 227 findings from the peptide KB as of May 25, 2026.

All recommendations are based on publicly available research and clinical practitioner reports. This is not medical advice. Consult a qualified healthcare provider before starting any peptide protocol.